SpecialtiesQuestion

What specific side effects would prompt you to stop teplizumab (TZIELD) therapy in patients aiming to delay the onset of stage 3 type 1 diabetes mellitus?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

How has the use of CGMs informed or improved your management of patients with pre diabetes or diabetes not on insulin?

Do you avoid the use of GLP-1 R agonist therapy for treatment of obesity in patients with known gastroparesis?

With the advent of GLP-1 receptor agonist therapy, when (if ever) do you consider adding pioglitazone to patients' diabetes regimen?

Do you consider adding a GLP-1 receptor agonist to insulin therapy in a patient with newly diagnosed LADA who has not yet progressed to insulin dependence?

How do you counsel patients on their risk of retinopathy or vision loss when starting GLP-1 R agonists for diabetes management?

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.